去痰薬の世界市場：業界分析、規模、シェア、成長、動向、予測（2024年～2034年）

去痰薬市場- 調査範囲

TMRの調査レポート「去痰薬の世界市場」は、2024年～2034年の予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018年～2034年の世界の去痰薬市場の収益と予測を提供しています。また、2024年～2034年の世界の去痰薬市場の複合年間成長率（CAGR%）も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、去痰薬市場を推察しました。

当レポートでは、世界の去痰薬市場の競合情勢について調査しています。世界の去痰薬市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTなどが、本レポートで紹介されている世界の去痰薬市場における企業の属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

• イントロダクション
• 概要
• 市場力学
• 世界の市場分析と予測（2020年～2034年）

第5章 主要洞察

• パイプライン分析
• 主要製品/ブランド分析
• 主要M&A
• COVID-19による産業への影響

第6章 世界の市場分析と予測：薬剤タイプ別

• イントロダクションと定義
• 主な調査結果・発展
• 市場金額予測：薬剤タイプ別（2020年～2034年）
  • 分泌促進剤
  • 粘液溶解薬
• 市場の魅力：薬剤タイプ別

第7章 世界の市場分析と予測：剤形別

• イントロダクションと定義
• 主な調査結果・発展
• 市場金額予測：剤形別（2020年～2034年）
  • 経口固形剤
  • 経口液剤
  • 吸入剤
• 市場の魅力：剤形別

第8章 世界の市場分析と予測：タイプ別

• イントロダクションと定義
• 主な調査結果・発展
• 市場金額予測：タイプ別（2020年～2034年）
  • 市販薬
  • 処方薬
• 市場の魅力：タイプ別

第9章 世界の市場分析と予測：流通チャネル別

• イントロダクションと定義
• 主な調査結果・発展
• 市場金額予測：流通チャネル別（2020年～2034年）
  • 院内薬局
  • 小売薬局
  • オンライン薬局
• 市場の魅力：流通チャネル別

第10章 世界の市場分析と予測：地域別

• 主な調査結果
• 市場金額予測：地域別（2020年～2034年）
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ
• 市場の魅力：地域別

第11章 北米の市場分析と予測

第12章 欧州の市場分析と予測

第13章 アジア太平洋の市場分析と予測

第14章 ラテンアメリカの市場分析と予測

第15章 中東・アフリカの市場分析と予測

第16章 競合情勢

• 市場企業-競合マトリックス（企業階層と規模別）
• 市場シェア分析：企業別（2023年）
• 企業プロファイル
  • Abbott Laboratories
  • Acella Pharmaceuticals, LLC
  • AstraZeneca plc
  • Cipla Limited
  • Dabur India Ltd.
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson
  • The Merck Group
  • Pfizer Inc.
  • The Procter & Gamble Company
  • Reckitt Benckiser Group PLC
  • Sanofi S.A.

List of Tables

• Table 01: Global Expectorant Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
• Table 02: Global Expectorant Drugs Market Size (US$ Bn) Forecast, by Dosage Form, 2020-2034
• Table 03: Global Expectorant Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
• Table 04: Global Expectorant Drugs Market Size (US$ Bn) Forecast, by Type, 2020-2034
• Table 05: Global Expectorant Drugs Market Size (US$ Bn) Forecast, by Region, 2020-2034
• Table 06: North America Expectorant Drugs Market Size (US$ Bn) Forecast, by Country, 2020-2034
• Table 07: North America Expectorant Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
• Table 08: North America Expectorant Drugs Market Size (US$ Bn) Forecast, by Dosage Form, 2020-2034
• Table 09: North America Expectorant Drugs Market Size (US$ Bn) Forecast, by Type, 2020-2034
• Table 10: North America Expectorant Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
• Table 11: Europe Expectorant Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
• Table 12: Europe Expectorant Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
• Table 13: Europe Expectorant Drugs Market Size (US$ Bn) Forecast, by Dosage Form, 2020-2034
• Table 14: Europe Expectorant Drugs Market Size (US$ Bn) Forecast, by Type, 2020-2034
• Table 15: Europe Expectorant Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
• Table 16: Asia Pacific Expectorant Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
• Table 17: Asia Pacific Expectorant Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
• Table 18: Asia Pacific Expectorant Drugs Market Size (US$ Bn) Forecast, by Dosage Form, 2020-2034
• Table 19: Asia Pacific Expectorant Drugs Market Size (US$ Bn) Forecast, by Type, 2020-2034
• Table 20: Asia Pacific Expectorant Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
• Table 21: Latin America Expectorant Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
• Table 22: Latin America Expectorant Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
• Table 23: Latin America Expectorant Drugs Market Size (US$ Bn) Forecast, by Dosage Form, 2020-2034
• Table 24: Latin America Expectorant Drugs Market Size (US$ Bn) Forecast, by Type, 2020-2034
• Table 25: Latin America Expectorant Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
• Table 26: Middle East & Africa Expectorant Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
• Table 27: Middle East & Africa Expectorant Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
• Table 28: Middle East & Africa Expectorant Drugs Market Size (US$ Bn) Forecast, by Dosage Form, 2020-2034
• Table 29: Middle East & Africa Expectorant Drugs Market Size (US$ Bn) Forecast, by Type, 2020-2034
• Table 30: Middle East & Africa Expectorant Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

List of Figures

• Figure 01: Global Expectorant Drugs Market Size (US$ Bn), by Region, 2023 and 2034
• Figure 02: Global Expectorant Drugs Market Revenue (US$ Bn), by Drug Type, 2023
• Figure 03: Global Expectorant Drugs Market Value Share, by Drug Type, 2023
• Figure 04: Global Expectorant Drugs Market Revenue (US$ Bn), by Dosage Form, 2023
• Figure 05: Global Expectorant Drugs Market Value Share, by Dosage Form, 2023
• Figure 06: Global Expectorant Drugs Market Revenue (US$ Bn), by Type, 2023
• Figure 07: Global Expectorant Drugs Market Value Share, by Type, 2023
• Figure 08: Global Expectorant Drugs Market Revenue (US$ Bn), by Distribution Channel, 2023
• Figure 09: Global Expectorant Drugs Market Value Share, by Distribution Channel, 2023
• Figure 10: Global Expectorant Drugs Market Value Share, by Region, 2023
• Figure 11: Global Expectorant Drugs Market Value (US$ Bn) Forecast, 2020-2034
• Figure 12: Global Expectorant Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
• Figure 13: Global Expectorant Drugs Market Attractiveness Analysis, by Drug Type, 2024-2034
• Figure 14: Global Expectorant Drugs Market Value Share Analysis, by Dosage Form, 2023 and 2034
• Figure 15: Global Expectorant Drugs Market Attractiveness Analysis, by Dosage Form, 2024-2034
• Figure 16: Global Expectorant Drugs Market Value Share Analysis, by Type, 2023 and 2034
• Figure 17: Global Expectorant Drugs Market Attractiveness Analysis, by Type, 2024-2034
• Figure 18: Global Expectorant Drugs Market Revenue (US$ Bn), by Distribution Channel, 2023
• Figure 19: Global Expectorant Drugs Market Value Share, by Distribution Channel, 2023
• Figure 20: Global Expectorant Drugs Market Value Share Analysis, by Region, 2023 and 2034
• Figure 21: Global Expectorant Drugs Market Attractiveness Analysis, by Region, 2024-2034
• Figure 22: North America Expectorant Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
• Figure 23: North America Expectorant Drugs Market Attractiveness Analysis, by Country, 2024-2034
• Figure 24: North America Expectorant Drugs Market Value Share Analysis, by Country, 2023 and 2034
• Figure 25: North America Expectorant Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
• Figure 26: North America Expectorant Drugs Market Value Share Analysis, by Dosage Form, 2023 and 2034
• Figure 27: North America Expectorant Drugs Market Value Share Analysis, by Type, 2023 and 2034
• Figure 28: North America Expectorant Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
• Figure 29: North America Expectorant Drugs Market Attractiveness Analysis, by Drug Type, 2024-2034
• Figure 30: North America Expectorant Drugs Market Attractiveness Analysis, by Dosage Form, 2024-2034
• Figure 31: North America Expectorant Drugs Market Attractiveness Analysis, by Type, 2024-2034
• Figure 32: North America Expectorant Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
• Figure 33: Europe Expectorant Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
• Figure 34: Europe Expectorant Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
• Figure 35: Europe Expectorant Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
• Figure 36: Europe Expectorant Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
• Figure 37: Europe Expectorant Drugs Market Value Share Analysis, by Dosage Form, 2023 and 2034
• Figure 38: Europe Expectorant Drugs Market Value Share Analysis, by Type, 2023 and 2034
• Figure 39: Europe Expectorant Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
• Figure 40: Europe Expectorant Drugs Market Attractiveness Analysis, by Drug Type, 2024-2034
• Figure 41: Europe Expectorant Drugs Market Attractiveness Analysis, by Dosage Form, 2024-2034
• Figure 42: Europe Expectorant Drugs Market Attractiveness Analysis, by Type, 2024-2034
• Figure 43: Europe Expectorant Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
• Figure 44: Asia Pacific Expectorant Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
• Figure 45: Asia Pacific Expectorant Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
• Figure 46: Asia Pacific Expectorant Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
• Figure 47: Asia Pacific Expectorant Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
• Figure 48: Asia Pacific Expectorant Drugs Market Value Share Analysis, by Dosage Form, 2023 and 2034
• Figure 49: Asia Pacific Expectorant Drugs Market Value Share Analysis, by Type, 2023 and 2034
• Figure 50: Asia Pacific Expectorant Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
• Figure 51: Asia Pacific Expectorant Drugs Market Attractiveness Analysis, by Drug Type, 2024-2034
• Figure 52: Asia Pacific Expectorant Drugs Market Attractiveness Analysis, by Dosage Form, 2024-2034
• Figure 53: Asia Pacific Expectorant Drugs Market Attractiveness Analysis, by Type, 2024-2034
• Figure 54: Asia Pacific Expectorant Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2034
• Figure 55: Latin America Expectorant Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
• Figure 56: Latin America Expectorant Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
• Figure 57: Latin America Expectorant Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
• Figure 58: Latin America Expectorant Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
• Figure 59: Latin America Expectorant Drugs Market Value Share Analysis, by Dosage Form, 2023 and 2034
• Figure 60: Latin America Expectorant Drugs Market Value Share Analysis, by Type, 2023 and 2034
• Figure 61: Latin America Expectorant Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
• Figure 62: Latin America Expectorant Drugs Market Attractiveness Analysis, by Drug Type, 2024-2034
• Figure 63: Latin America Expectorant Drugs Market Attractiveness Analysis, by Dosage Form, 2024-2034
• Figure 64: Latin America Expectorant Drugs Market Attractiveness Analysis, by Type, 2024-2034
• Figure 65: Latin America Expectorant Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
• Figure 66: Middle East & Africa Expectorant Drugs Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
• Figure 67: Middle East & Africa Expectorant Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
• Figure 68: Middle East & Africa Expectorant Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
• Figure 69: Middle East & Africa Expectorant Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
• Figure 70: Middle East & Africa Expectorant Drugs Market Value Share Analysis, by Dosage Form, 2023 and 2034
• Figure 71: Middle East & Africa Expectorant Drugs Market Value Share Analysis, by Type, 2023 and 2034
• Figure 72: Middle East & Africa Expectorant Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
• Figure 73: Middle East & Africa Expectorant Drugs Market Attractiveness Analysis, by Drug Type, 2024-2034
• Figure 74: Middle East & Africa Expectorant Drugs Market Attractiveness Analysis, by Dosage Form, 2024-2034
• Figure 75: Middle East & Africa Expectorant Drugs Market Attractiveness Analysis, by Type, 2024-2034
• Figure 76: Middle East & Africa Expectorant Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034

Expectorant Drugs Market - Scope of Report

TMR's report on the global expectorant drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global expectorant drugs market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global expectorant drugs market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the expectorant drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global expectorant drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global expectorant drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global expectorant drugs market.

The report delves into the competitive landscape of the global expectorant drugs market. Key players operating in the global expectorant drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global expectorant drugs market profiled in this report.

Key Questions Answered in Global expectorant drugs Market Report:

• What is the sales/revenue generated by expectorant drugs across all regions during the forecast period?
• What are the opportunities in the global expectorant drugs market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Expectorant Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global expectorant drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global expectorant drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global expectorant drugs market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Expectorant Drugs Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Expectorant Drugs Market Analysis and Forecast, 2020-2034

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Product/Brand Analysis
• 5.3. Key Mergers & Acquisitions
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global Expectorant Drugs Market Analysis and Forecast, by Drug Type

• 6.1. Introduction and Definitions
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Drug Type, 2020-2034
  • 6.3.1. Secretion Enhancer
    • 6.3.1.1. Potassium Citrate
    • 6.3.1.2. Sodium Citrate
    • 6.3.1.3. Guaiphenesin
    • 6.3.1.4. Others (Ammonium Chloride, etc.)
  • 6.3.2. Mucolytics
    • 6.3.2.1. Bromhexine
    • 6.3.2.2. Amroxol
    • 6.3.2.3. Acetyl Cysteine
    • 6.3.2.4. Carbocisteineurine
• 6.4. Market Attractiveness, by Drug Type

7. Global Expectorant Drugs Market Analysis and Forecast, by Dosage Form

• 7.1. Introduction and Definitions
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Dosage Form, 2020-2034
  • 7.3.1. Oral Solid
    • 7.3.1.1. Powder & Granules
    • 7.3.1.2. Tablet
    • 7.3.1.3. Capsule
    • 7.3.1.4. Lozenge
  • 7.3.2. Oral Liquid
    • 7.3.2.1. Syrup
    • 7.3.2.2. Solution
    • 7.3.2.3. Suspension
    • 7.3.2.4. Elixir
  • 7.3.3. Inhalant
• 7.4. Market Attractiveness, by Dosage Form

8. Global Expectorant Drugs Market Analysis and Forecast, by Type

• 8.1. Introduction and Definitions
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Type, 2020-2034
  • 8.3.1. Over-the-Counter Drugs
  • 8.3.2. Prescription Drugs
• 8.4. Market Attractiveness, by Type

9. Global Expectorant Drugs Market Analysis and Forecast, by Distribution Channel

• 9.1. Introduction and Definitions
• 9.2. Key Findings/Developments
• 9.3. Market Value Forecast, by Distribution Channel, 2020-2034
  • 9.3.1. Hospital Pharmacies
  • 9.3.2. Retail Pharmacies
  • 9.3.3. Online Pharmacies
• 9.4. Market Attractiveness, by Distribution Channel

10. Global Expectorant Drugs Market Analysis and Forecast, by Region

• 10.1. Key Findings
• 10.2. Market Value Forecast, by Region, 2020-2034
  • 10.2.1. North America
  • 10.2.2. Europe
  • 10.2.3. Asia Pacific
  • 10.2.4. Latin America
  • 10.2.5. Middle East & Africa
• 10.3. Market Attractiveness, by Region

11. North America Expectorant Drugs Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Drug Type, 2020-2034
  • 11.2.1. Secretion Enhancer
    • 11.2.1.1. Potassium Citrate
    • 11.2.1.2. Sodium Citrate
    • 11.2.1.3. Guaiphenesin
    • 11.2.1.4. Others (Ammonium Chloride, etc.)
  • 11.2.2. Mucolytics
    • 11.2.2.1. Bromhexine
    • 11.2.2.2. Amroxol
    • 11.2.2.3. Acetyl Cysteine
    • 11.2.2.4. Carbocisteineurine
• 11.3. Market Attractiveness, by Drug Type
• 11.4. Market Value Forecast, by Dosage Form, 2020-2034
  • 11.4.1. Oral Solid
    • 11.4.1.1. Powder & Granules
    • 11.4.1.2. Tablet
    • 11.4.1.3. Capsule
    • 11.4.1.4. Lozenge
  • 11.4.2. Oral Liquid
    • 11.4.2.1. Syrup
    • 11.4.2.2. Solution
    • 11.4.2.3. Suspension
    • 11.4.2.4. Elixir
  • 11.4.3. Inhalant
• 11.5. Market Attractiveness, by Dosage Form
• 11.6. Market Value Forecast, by Type, 2020-2034
  • 11.6.1. Over-the-Counter Drugs
  • 11.6.2. Prescription Drugs
• 11.7. Market Attractiveness, by Type
• 11.8. Market Value Forecast, by Distribution Channel, 2020-2034
  • 11.8.1. Hospital Pharmacies
  • 11.8.2. Retail Pharmacies
  • 11.8.3. Online Pharmacies
• 11.9. Market Attractiveness, by Distribution Channel
• 11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 11.10.1. U.S.
  • 11.10.2. Canada
• 11.11. Market Attractiveness Analysis
  • 11.11.1. By Drug Type
  • 11.11.2. By Dosage Form
  • 11.11.3. By Type
  • 11.11.4. By Distribution Channel
  • 11.11.5. By Country

12. Europe Expectorant Drugs Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Drug Type, 2020-2034
  • 12.2.1. Secretion Enhancer
    • 12.2.1.1. Potassium Citrate
    • 12.2.1.2. Sodium Citrate
    • 12.2.1.3. Guaiphenesin
    • 12.2.1.4. Others (Ammonium Chloride, etc.)
  • 12.2.2. Mucolytics
    • 12.2.2.1. Bromhexine
    • 12.2.2.2. Amroxol
    • 12.2.2.3. Acetyl Cysteine
    • 12.2.2.4. Carbocisteineurine
• 12.3. Market Attractiveness, by Drug Type
• 12.4. Market Value Forecast, by Dosage Form, 2020-2034
  • 12.4.1. Oral Solid
    • 12.4.1.1. Powder & Granules
    • 12.4.1.2. Tablet
    • 12.4.1.3. Capsule
    • 12.4.1.4. Lozenge
  • 12.4.2. Oral Liquid
    • 12.4.2.1. Syrup
    • 12.4.2.2. Solution
    • 12.4.2.3. Suspension
    • 12.4.2.4. Elixir
  • 12.4.3. Inhalant
• 12.5. Market Attractiveness, by Dosage Form
• 12.6. Market Value Forecast, by Type, 2020-2034
  • 12.6.1. Over-the-Counter Drugs
  • 12.6.2. Prescription Drugs
• 12.7. Market Attractiveness, by Type
• 12.8. Market Value Forecast, by Distribution Channel, 2020-2034
  • 12.8.1. Hospital Pharmacies
  • 12.8.2. Retail Pharmacies
  • 12.8.3. Online Pharmacies
• 12.9. Market Attractiveness, by Distribution Channel
• 12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 12.10.1. Germany
  • 12.10.2. U.K.
  • 12.10.3. France
  • 12.10.4. Italy
  • 12.10.5. Spain
  • 12.10.6. Rest of Europe
• 12.11. Market Attractiveness Analysis
  • 12.11.1. By Drug Type
  • 12.11.2. By Dosage Form
  • 12.11.3. By Type
  • 12.11.4. By Distribution Channel
  • 12.11.5. By Country/Sub-region

13. Asia Pacific Expectorant Drugs Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Drug Type, 2020-2034
  • 13.2.1. Secretion Enhancer
    • 13.2.1.1. Potassium Citrate
    • 13.2.1.2. Sodium Citrate
    • 13.2.1.3. Guaiphenesin
    • 13.2.1.4. Others (Ammonium Chloride, etc.)
  • 13.2.2. Mucolytics
    • 13.2.2.1. Bromhexine
    • 13.2.2.2. Amroxol
    • 13.2.2.3. Acetyl Cysteine
    • 13.2.2.4. Carbocisteineurine
• 13.3. Market Attractiveness, by Drug Type
• 13.4. Market Value Forecast, by Dosage Form, 2020-2034
  • 13.4.1. Oral Solid
    • 13.4.1.1. Powder & Granules
    • 13.4.1.2. Tablet
    • 13.4.1.3. Capsule
    • 13.4.1.4. Lozenge
  • 13.4.2. Oral Liquid
    • 13.4.2.1. Syrup
    • 13.4.2.2. Solution
    • 13.4.2.3. Suspension
    • 13.4.2.4. Elixir
  • 13.4.3. Inhalant
• 13.5. Market Attractiveness, by Dosage Form
• 13.6. Market Value Forecast, by Type, 2020-2034
  • 13.6.1. Over-the-Counter Drugs
  • 13.6.2. Prescription Drugs
• 13.7. Market Attractiveness, by Type
• 13.8. Market Value Forecast, by Distribution Channel, 2020-2034
  • 13.8.1. Hospital Pharmacies
  • 13.8.2. Retail Pharmacies
  • 13.8.3. Online Pharmacies
• 13.9. Market Attractiveness, by Distribution Channel
• 13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 13.10.1. China
  • 13.10.2. Japan
  • 13.10.3. India
  • 13.10.4. Australia & New Zealand
  • 13.10.5. Rest of Asia Pacific
• 13.11. Market Attractiveness Analysis
  • 13.11.1. By Drug Type
  • 13.11.2. By Dosage Form
  • 13.11.3. By Type
  • 13.11.4. By Distribution Channel
  • 13.11.5. By Country/Sub-region

14. Latin America Expectorant Drugs Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Drug Type, 2020-2034
  • 14.2.1. Secretion Enhancer
    • 14.2.1.1. Potassium Citrate
    • 14.2.1.2. Sodium Citrate
    • 14.2.1.3. Guaiphenesin
    • 14.2.1.4. Others (Ammonium Chloride, etc.)
  • 14.2.2. Mucolytics
    • 14.2.2.1. Bromhexine
    • 14.2.2.2. Amroxol
    • 14.2.2.3. Acetyl Cysteine
    • 14.2.2.4. Carbocisteineurine
• 14.3. Market Attractiveness, by Drug Type
• 14.4. Market Value Forecast, by Dosage Form, 2020-2034
  • 14.4.1. Oral Solid
    • 14.4.1.1. Powder & Granules
    • 14.4.1.2. Tablet
    • 14.4.1.3. Capsule
    • 14.4.1.4. Lozenge
  • 14.4.2. Oral Liquid
    • 14.4.2.1. Syrup
    • 14.4.2.2. Solution
    • 14.4.2.3. Suspension
    • 14.4.2.4. Elixir
  • 14.4.3. Inhalant
• 14.5. Market Attractiveness, by Dosage Form
• 14.6. Market Value Forecast, by Type, 2020-2034
  • 14.6.1. Over-the-Counter Drugs
  • 14.6.2. Prescription Drugs
• 14.7. Market Attractiveness, by Type
• 14.8. Market Value Forecast, by Distribution Channel, 2020-2034
  • 14.8.1. Hospital Pharmacies
  • 14.8.2. Retail Pharmacies
  • 14.8.3. Online Pharmacies
• 14.9. Market Attractiveness, by Distribution Channel
• 14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 14.10.1. Brazil
  • 14.10.2. Mexico
  • 14.10.3. Rest of Latin America
• 14.11. Market Attractiveness Analysis
  • 14.11.1. By Drug Type
  • 14.11.2. By Dosage Form
  • 14.11.3. By Type
  • 14.11.4. By Distribution Channel
  • 14.11.5. By Country/Sub-region

15. Middle East & Africa Expectorant Drugs Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast, by Drug Type, 2020-2034
  • 15.2.1. Secretion Enhancer
    • 15.2.1.1. Potassium Citrate
    • 15.2.1.2. Sodium Citrate
    • 15.2.1.3. Guaiphenesin
    • 15.2.1.4. Others (Ammonium Chloride, etc.)
  • 15.2.2. Mucolytics
    • 15.2.2.1. Bromhexine
    • 15.2.2.2. Amroxol
    • 15.2.2.3. Acetyl Cysteine
    • 15.2.2.4. Carbocisteineurine
• 15.3. Market Attractiveness, by Drug Type
• 15.4. Market Value Forecast, by Dosage Form, 2020-2034
  • 15.4.1. Oral Solid
    • 15.4.1.1. Powder & Granules
    • 15.4.1.2. Tablet
    • 15.4.1.3. Capsule
    • 15.4.1.4. Lozenge
  • 15.4.2. Oral Liquid
    • 15.4.2.1. Syrup
    • 15.4.2.2. Solution
    • 15.4.2.3. Suspension
    • 15.4.2.4. Elixir
  • 15.4.3. Inhalant
• 15.5. Market Attractiveness, by Dosage Form
• 15.6. Market Value Forecast, by Type, 2020-2034
  • 15.6.1. Over-the-Counter Drugs
  • 15.6.2. Prescription Drugs
• 15.7. Market Attractiveness, by Type
• 15.8. Market Value Forecast, by Distribution Channel, 2020-2034
  • 15.8.1. Hospital Pharmacies
  • 15.8.2. Retail Pharmacies
  • 15.8.3. Online Pharmacies
• 15.9. Market Attractiveness, by Distribution Channel
• 15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 15.10.1. GCC Countries
  • 15.10.2. South Africa
  • 15.10.3. Rest of Middle East & Africa
• 15.11. Market Attractiveness Analysis
  • 15.11.1. By Drug Type
  • 15.11.2. By Dosage Form
  • 15.11.3. By Type
  • 15.11.4. By Distribution Channel
  • 15.11.5. By Country/Sub-region

16. Competition Landscape

• 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
• 16.2. Market Share Analysis, by Company (2023)
• 16.3. Company Profiles
  • 16.3.1. Abbott Laboratories
    • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.1.2. Product Portfolio
    • 16.3.1.3. Financial Overview
    • 16.3.1.4. SWOT Analysis
    • 16.3.1.5. Strategic Overview
  • 16.3.2. Acella Pharmaceuticals, LLC
    • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.2.2. Product Portfolio
    • 16.3.2.3. Financial Overview
    • 16.3.2.4. SWOT Analysis
    • 16.3.2.5. Strategic Overview
  • 16.3.3. AstraZeneca plc
    • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.3.2. Product Portfolio
    • 16.3.3.3. Financial Overview
    • 16.3.3.4. SWOT Analysis
    • 16.3.3.5. Strategic Overview
  • 16.3.4. Cipla Limited
    • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.4.2. Product Portfolio
    • 16.3.4.3. Financial Overview
    • 16.3.4.4. SWOT Analysis
    • 16.3.4.5. Strategic Overview
  • 16.3.5. Dabur India Ltd.
    • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.5.2. Product Portfolio
    • 16.3.5.3. Financial Overview
    • 16.3.5.4. SWOT Analysis
    • 16.3.5.5. Strategic Overview
  • 16.3.6. Glenmark Pharmaceuticals Limited
    • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.6.2. Product Portfolio
    • 16.3.6.3. Financial Overview
    • 16.3.6.4. SWOT Analysis
    • 16.3.6.5. Strategic Overview
  • 16.3.7. Johnson & Johnson
    • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.7.2. Product Portfolio
    • 16.3.7.3. Financial Overview
    • 16.3.7.4. SWOT Analysis
    • 16.3.7.5. Strategic Overview
  • 16.3.8. The Merck Group
    • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.8.2. Product Portfolio
    • 16.3.8.3. Financial Overview
    • 16.3.8.4. SWOT Analysis
    • 16.3.8.5. Strategic Overview
  • 16.3.9. Pfizer Inc.
    • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.9.2. Product Portfolio
    • 16.3.9.3. Financial Overview
    • 16.3.9.4. SWOT Analysis
    • 16.3.9.5. Strategic Overview
  • 16.3.10. The Procter & Gamble Company
    • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.10.2. Product Portfolio
    • 16.3.10.3. Financial Overview
    • 16.3.10.4. SWOT Analysis
    • 16.3.10.5. Strategic Overview
  • 16.3.11. Reckitt Benckiser Group PLC
    • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.11.2. Product Portfolio
    • 16.3.11.3. Financial Overview
    • 16.3.11.4. SWOT Analysis
    • 16.3.11.5. Strategic Overview
  • 16.3.12. Sanofi S.A.
    • 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.12.2. Product Portfolio
    • 16.3.12.3. Financial Overview
    • 16.3.12.4. SWOT Analysis
    • 16.3.12.5. Strategic Overview